AlphAIalphai — Financial news for AI agents
investing.comAUG 36 min read$LNTH

Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

Reuters reports Curium will buy Lantheus Holdings in a deal worth up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus rights for up to $12 more per share if sales targets are met by 2030. Total $114.50 per share is a ~14.9% premium to $99.64. Deal expected to close in H1 2027.

Original reporting
investing.com
Published Aug 3, 2026, 3:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMergers & acquisitions
Primary signal
$LNTH
Bullish
high confidence
Mentioned
$LNTH
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$LNTHBullishHigh
01

Why it matters

The article provides concrete acquisition economics (upfront cash, potential earnout, premium), deal size, financing approach, and a regulatory-scrutiny risk flag, which are key inputs for merger-arbitrage and risk management.

02

Market read

A disclosed, large radiopharma acquisition with specific per-share economics and a stated closing window creates immediate tradable information for both target and acquirer risk.

03

What to watch

The earnout tied to 2030 sales targets can create uncertainty about achievable revenue, affecting both merger-arb pricing and long-term valuation assumptions.

Relevance 9/10Novelty 9/10Timing: deal announced Monday, with closing expected in 1H 2027

Background

Radiopharmaceuticals are described as a hot healthcare dealmaking area, with prior transactions cited (RayzeBio, Fusion Pharmaceuticals, Point Biopharma).

Company-level read

Ticker impact

$LNTHBullishHigh confidence
Context

Lantheus agreed to be acquired by Curium at $102.50 per share cash, with potential $12 more per share tied to 2030 sales targets.

Expected impact

Expect LNTH to trade with deal-spread dynamics, likely supported by the stated premium but volatile on regulatory/financing headlines.

Evidence & confidence

The article discloses specific per-share consideration, premium vs last close, and expected close in 1H 2027, which directly drives merger-arb and headline risk.

Market effects

Sector

Signals continued consolidation and premium pricing in diagnostic radiopharmaceuticals, potentially resetting deal expectations for peers.

Regional

Primarily US healthcare M&A sentiment, with spillover to US-listed radiopharma and imaging-adjacent names.

Global

Reinforces global appetite for radiopharma assets, though the disclosed transaction is US-focused.

Counterpoint

What could challenge this read

The headline premium may be less compelling if regulatory scrutiny delays or derails the transaction, widening the probability-weighted deal spread.

Key entities

  • acquirer
    Curium

    Private equity-backed radiopharmaceutical company (CapVest Partners) agreeing to buy Lantheus for up to $8 billion.

  • target
    Lantheus Holdings

    Radiopharmaceutical peer whose shareholders receive $102.50 per share cash plus potential additional consideration tied to 2030 sales targets.

  • sponsor
    CapVest Partners

    Private equity firm backing Curium, relevant to financing and deal execution context.

  • analyst
    B. Riley Securities (Yuan Zhi)

    Commentary that the upfront price is fair but below where some investors expected.

  • analyst
    Jones Trading (Justin Walsh)

    Notes relatively high regulatory scrutiny risk due to both firms being major diagnostic radiopharmaceutical players.

Read at source← All news

Related articles

AUG 6
$LNTHMed

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.

financialcontent.com5 min
AUG 6
$LNTHHighAI 10/10

Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad

SEC EDGAR 8-K6 min
AUG 4
$LNTHHighAI 9/10

Curium to buy Lantheus in all

Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.

pharmaceutical-business-review.com6 min
AUG 3
$LNTHMed

TD Cowen downgrades Lantheus stock to hold on Curium deal view

TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.

investing.com4 min
AUG 3
$LNTHHighAI 9/10

Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.

rttnews.com4 min